WallStSmart
RARE

Ultragenyx

NASDAQ: RARE · HEALTHCARE · BIOTECHNOLOGY

$24.18
-1.43% today

Updated 2026-04-29

Market cap
$2.38B
P/E ratio
P/S ratio
3.53x
EPS (TTM)
$-5.83
Dividend yield
52W range
$18 – $42
Volume
2.0M

Ultragenyx (RARE) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
-11.5%
Last 4 quarters
Revenue YoY growth
+25.5%
Most recent quarter
EPS YoY growth
+7.2%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-6.5%
Last 3 reports
Positive reaction rate
0%
0 of 3 quarters
Largest single-day move
-14.1%
2026-02-12
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-02-12$-1.29-12.2%$23.88$20.52-14.1%
2025-11-06$-1.81-49.6%$31.87$30.63-3.9%
2025-08-05$-1.17+11.4%$28.46$28.05-1.4%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-1.15$-1.29-12.2%$207.00M+25.5%
2025-09-30$-1.21$-1.81-49.6%$159.93M+14.7%
2025-06-30$-1.32$-1.17+11.4%$166.50M+13.2%
2025-03-31$-1.64$-1.57+4.3%$139.29M+28.0%
2024-12-31$-1.27$-1.39-9.4%$164.88M+29.4%
2024-09-30$-1.47$-1.40+4.8%$139.49M+42.3%
2024-06-30$-1.69$-1.52+10.1%$147.03M+35.7%
2024-03-31$-1.73$-2.03-17.3%$108.83M
2023-12-31$-1.62$-1.52+6.2%$127.39M
2023-09-30$-2.08$-2.23-7.2%$98.05M
2023-06-30$-2.07$-2.25-8.7%$108.31M

Frequently asked questions

Has Ultragenyx beaten earnings estimates?
Ultragenyx has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of -11.5% over the last 4 quarters.
How does RARE stock react to earnings?
RARE stock has moved an average of -6.5% in the trading day following earnings over its last 3 reports, with positive reactions in 0% of those quarters.
What is Ultragenyx's revenue growth rate?
Ultragenyx reported year-over-year revenue growth of +25.5% in its most recent quarter, with EPS growing +7.2% year-over-year.